- Reference code :
- wf291
- Published date :
-
21 October 1999
- Expired date :
-
08 March 2027
AstraZeneca today announced that a regulatory application for H199/18, a new proton pump inhibitor (PPI), has been submitted to authorities in Sweden, acting as rapporteur country in the European Union's mutual recognition procedure. The new pharmaceutical contains the active substance esomeprazole.
This marks the first step in a global application process, which will be followed by applications in the USA, among other countries.
"H199/18 is the first PPI synthesised as an isomer to be available for clinical use, and it is a further evolution in PPI therapy beyond omeprazole", said Dr Martin Nicklasson, Executive Vice President of AstraZeneca's GI Franchise. "This is a significant milestone for AstraZeneca's business in the gastrointestinal area."
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
